FDA's NDA REWRITE MAY INCLUDE "END OF REVIEW CONFERENCE," FDA Acting Com. Novitch stated at a recent meeting of the Pharmaceutical Mfrs. Assn. Medical Section. Noting that the agency is seeking to expand communications between FDA and drug sponsors, Novitch said FDA is "considering adding a standard meeting called an 'end of review conference,'" to the NDA regs. He explained that the conference "would occur routinely, at the sponsor's option, after FDA has completed review of an NDA and has issued an action letter." Novitch said the goal of such a meeting would be "to reach a meeting of the minds on what additional data or analyses are necessary for a drug to be approved." He also pointed out that the new regs will establish, as PMA and others suggested, an ombudsman "to aid drug sponsors in resolving impasses of a procedural or administrative nature." He said an ombudsman would handle "difficulties in setting up meetings, getting responses to letters, or determining the status of an application in the review process." Novitch told attendees at the March 19 meeting that the NDA rewrite is at HHS and FDA is "very hopeful that a final rule might be published by early summer." Another priority at FDA is a revamping of the adverse drug reaction reporting system, Novitch observed. "Our goal is that by the end of this, we will have in place an on-line, interactive data base that will allow for immediate input, editing, and data retrieval," he stated. "Our new system will provide for accelerated data entry and will also allow for desired output on an 'as needed' basis." Novitch said the agency is revising the computer system and reorganizing paper flow internally.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
In this first of a two-part series of articles, US Pharmacopeia CEO Ronald T. Piervincenzi tells the Pink Sheet how the use of alternatives to animal testing in drug development is gaining traction and discusses the challenges that exist.
The Senate Health, Education, Labor and Pensions Committee voted to advance Monarez's nomination to lead the CDC as the agency announced the largest US measles outbreak in 22 years.
The Pediatric Advisory Committee supported routine safety monitoring for three vaccines and 21 drugs, but the panel’s consumer representative said adverse event reporting needs improvement and FDA literature reviews should include lawsuits as well as social media.
